SeqLL (SQL) Stock Price, News & Analysis

Company Overview

SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It focus on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provide solutions for various applications, such as biomarker discovery and diagnostic assay developments including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and research collaboration with True Bearing Diagnostics, Inc. performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease. Further, it has collaboration agreement with The Bernstein Laboratory to address fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine assisting in the development of new methods for chromatin interaction analysis in single nuclei, with single-molecule resolution; Weizmann Institute of Science for developed and applied innovative single-molecule technologies; and Tetracore, Inc. to provide with tSMS systems and onsite support. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.

Key Stats

• Today's Range: $4.99 to $5.20
• 50-Day Range: $2.99 to $6.60
• 52-Week Range: $6.50 to $96.00
• Volume: 2,353 shs
• Average Volume: 52,119 shs
• Market Capitalization: $1.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SQL Stock Analysis - Frequently Asked Questions

When did SeqLL's stock split?

SeqLL's stock reverse split on the morning of Thursday, August 31st 2023. The 1-40 reverse split was announced on Thursday, August 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did SeqLL IPO?

SeqLL (SQL) raised $11 million in an initial public offering on Friday, August 27th 2021. The company issued 2,315,789 shares at $4.25-$5.25 per share.

What other stocks do shareholders of SeqLL own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SeqLL investors own include NexOptic Technology (NXO), Chembio Diagnostics (CEMI), Traeger (COOK), IN8bio (INAB), CS Disco (LAW), Membership Collective Group (MCG) and Meta Platforms (META).

Company Calendar

• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SQL
• CUSIP: N/A
• CIK: 1605888
• Web: www.seqll.com
• Phone: 781-460-6016
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($16.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,090,000.00
• Net Margins: N/A
• Pretax Margin: -15,725.81%
• Return on Equity: -124.09%
• Return on Assets: -64.18%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 5.04
• Quick Ratio: 5.04

Sales & Book Value

• Annual Sales: $80,000.00
• Price / Sales: 24.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.70 per share
• Price / Book: 0.35

Miscellaneous

• Outstanding Shares: 381,000
• Free Float: 296,000
• Market Cap: $1.98 million
• Optionable: Not Optionable
• Beta: 1.34